Loading patent…
AssigneeGenmab A/S
InventorsJan G.J. van de Winkel, Marcus A. van Dijk, Janine Schuurman, Arnout F. Gerritsen, Ole Baadsgaard, Jorgen Petersen
Estimating the term…
Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
A method of treating psoriasis caused by the proinflammatory effects of human IL-15, comprising administering to a subject a monoclonal antibody or antigen binding portion thereof which binds to human IL-15, in an amount effective to treat the disorder, wherein the heavy chain variable region of the antibody comprises the amino acid sequence set forth in SEQ ID NO:2.
A method of treating psoriasis caused by the proinflammatory effects of human IL-15, comprising administering to a subject a monoclonal antibody or antigen binding portion thereof which binds to human IL-15, in an amount effective to treat the disorder, wherein the light chain variable region of the antibody comprises the amino acid sequence set forth in SEQ ID NO:4.
A method of treating psoriasis caused by the proinflammatory effects of human IL-15, comprising administering to a subject a monoclonal antibody or antigen binding portion thereof which binds to human IL-15, in an amount effective to treat the disorder, wherein the heavy and light chain variable regions of the antibody comprise the amino acid sequences set forth in SEQ ID NO:2 and SEQ ID NO:4, respectively, or amino acid sequences at least 80% identical thereto.
A method of treating psoriasis caused by the proinflammatory effects of human IL-15, comprising administering to a subject a monoclonal antibody or antigen binding portion thereof in an amount effective to treat the disorder, wherein the antibody binds an epitope on human IL-15 recognized by an antibody comprising heavy chain and human light chain variable regions comprising the amino acid sequences set forth in SEQ ID NO:2 and SEQ ID NO:4, respectively.
Dependencies are inferred from the claim text.